Biblio
Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. Clin Lymphoma Myeloma Leuk. 2015.
Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase. Blood Adv. 2020;4(21):5562-5573.
.
Impact of high molecular risk mutations on transplant outcomes in patients with myelofibrosis. Biol Blood Marrow Transplant. 2019.
Mobilization of leukemic cells using plerixafor as part of a myeloablative preparative regimen for patients with AML undergoing allografting: assessment of safety and tolerability. Biol Blood Marrow Transplant. 2019.
Modulation of canonical Wnt signaling regulates peribiliary mesenchymal identity during homeostasis and injury. Hepatol Commun. 2024;8(2).
. . A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis. Blood Adv. 2023.
Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965-1973.